Dimethyl Fumarate
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Dimethyl Fumarate |
| DrugBank ID | DB08908 |
| Brand Names (EU) | Tecfidera |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.76% |
Approved Indication (EMA)
Tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | relapsing-remitting multiple sclerosis | 98.76% | DL |
| 2 | progressive multiple sclerosis | 90.67% | DL |
| 3 | schwannoma of jugular foramen | 89.67% | DL |
| 4 | cervical neuroblastoma | 89.67% | DL |
| 5 | benign neoplasm of buccal mucosa | 89.44% | DL |
| 6 | jugular foramen meningioma | 89.31% | DL |
| 7 | benign neoplasm of tongue | 89.27% | DL |
| 8 | benign neoplasm of hypopharynx | 89.26% | DL |
| 9 | inner ear neoplasm | 89.23% | DL |
| 10 | benign neoplasm of floor of mouth | 89.19% | DL |
| 11 | nasal cavity inverting papilloma | 89.07% | DL |
| 12 | epiglottis neoplasm | 89.06% | DL |
| 13 | benign neoplasm of nasal cavity | 89.04% | DL |
| 14 | neoplasm of major salivary gland | 89.02% | DL |
| 15 | vestibulocochlear nerve neoplasm | 89.00% | DL |
| 16 | skull base neoplasm | 89.00% | DL |
| 17 | benign neoplasm of salivary gland | 88.93% | DL |
| 18 | benign neoplasm of oral cavity | 88.92% | DL |
| 19 | abducens nerve neoplasm | 88.84% | DL |
| 20 | cystic neoplasm | 88.79% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.